Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review

被引：0
|
作者：
Ann M. Murray
Jennifer I. Stern
Carrie E. Robertson
Chia-Chun Chiang
机构：
[1] Mayo Clinic,Department of Neurology
来源：
Current Pain and Headache Reports | 2022年 / 26卷
关键词：
Real-world studies; CGRP; Monoclonal antibody; CGRP receptor antagonist; Medication overuse; Chronic migraine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：783 / 794
页数：11
相关论文
共 50 条
  • [41] Real-world experience with CFTR modulator therapy
    Tuemmler, Burkhard
    Burgel, Pierre-Regis
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [42] Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
    Nicolas Vandenbussche
    Karolina Pisarek
    Koen Paemeleire
    The Journal of Headache and Pain, 24
  • [43] Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review
    Amira Salim
    Elise Hennessy
    Claire Sonneborn
    Olivia Hogue
    Sudipa Biswas
    MaryAnn Mays
    Aarushi Suneja
    Zubair Ahmed
    Ignacio F. Mata
    CNS Drugs, 2024, 38 : 481 - 491
  • [44] Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
    Bianca Raffaelli
    Maria Terhart
    Jasper Mecklenburg
    Lars Neeb
    Lucas Hendrik Overeem
    Anke Siebert
    Maureen Steinicke
    Uwe Reuter
    The Journal of Headache and Pain, 2022, 23
  • [45] Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
    Raffaelli, Bianca
    Terhart, Maria
    Mecklenburg, Jasper
    Neeb, Lars
    Overeem, Lucas Hendrik
    Siebert, Anke
    Steinicke, Maureen
    Reuter, Uwe
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [46] Three one-year cycles of treatment with CGRP-targeting monoclonal antibodies: a real-life study in a cohort of chronic migraine patients
    Vaghi, Gloria
    De Icco, Roberto
    Corrado, Michele
    Cammarota, Francescantonio
    Bighiani, Federico
    Brancaccio, Carla
    Guaschino, Elena
    Ghiotto, Natascia
    Tassorelli, Cristina
    Sances, Grazia
    CEPHALALGIA, 2023, 43 (1supp) : 227 - 228
  • [47] Real-world reductions in migraine and headache days after initiating fremanezumab for US patients with migraine and prior use of another monoclonal antibody targeting the CGRP pathway
    Driessen, M. T.
    Patterson-Lomba, O.
    Mu, F.
    Thompson, S. F.
    Seminerio, M. J.
    Carr, K.
    Sun, R.
    Totev, T.
    Yim, E.
    Ayyagari, R.
    Cohen, J. M.
    HEADACHE, 2021, 61 : 141 - 141
  • [48] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
    Andreas Straube
    Gregor Broessner
    Charly Gaul
    Xenia Hamann
    Joachim Hipp
    Torsten Kraya
    Lars Neeb
    The Journal of Headache and Pain, 24
  • [49] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Neeb, Lars
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [50] Real-World Effectiveness of Eptinezumab after Treatment with Subcutaneous CGRP Monoclonal Antibodies in Patients with Migraine
    Casaletto, Emily
    Yang, Qiu Zi
    Waters, John
    Curran, John
    Lowe, Austin
    Yuan, Hsiangkuo
    NEUROLOGY, 2023, 100 (17)
12345